US 10,828,294 C1 (236th)
Compositions and methods for weight loss in at risk patient populations
Preston Klassen, La Jolla, CA (US); and Kristin Taylor, San Diego, CA (US)
Filed by Nalpropion Pharmaceuticals LLC, Morristown, NJ (US)
Assigned to NALPROPION PHARMACEUTICALS LLC, Morristown, NJ (US)
Supplemental Examination Request No. 96/000,379, Sep. 29, 2021.
Supplemental Examination Request No. 96/000,378, Sep. 29, 2021.
Reexamination Certificate for Patent 10,828,294, issued Nov. 10, 2020, Appl. No. 16/356,657, Mar. 18, 2019.
Application 96/000,378 is a continuation of application No. 15/725,830, filed on Oct. 5, 2017, granted, now 10,231,964.
Application 15/725,830 is a continuation of application No. 14/839,792, filed on Aug. 28, 2015, granted, now 9,801,875.
Application 14/839,792 is a continuation of application No. 14/635,518, filed on Mar. 2, 2015, granted, now 9,119,850.
Application 14/635,518 is a continuation of application No. 14/322,810, filed on Jul. 2, 2014, granted, now 8,969,371.
Claims priority of provisional application 61/984,580, filed on Apr. 25, 2014.
Claims priority of provisional application 61/914,938, filed on Dec. 11, 2013.
Claims priority of provisional application 61/913,216, filed on Dec. 6, 2013.
Ex Parte Reexamination Certificate from Reexamination Ordered under 35 U.S.C. 257 issued on Dec. 1, 2023.
Int. Cl. A61K 31/485 (2006.01); A61P 9/10 (2006.01); A61P 43/00 (2006.01); A61P 9/00 (2006.01); A61P 9/06 (2006.01); A61P 3/04 (2006.01); A61P 3/06 (2006.01); A61P 3/10 (2006.01); A61P 9/12 (2006.01); A61P 9/04 (2006.01); A61K 9/48 (2006.01); A61K 31/137 (2006.01)
CPC A61K 31/485 (2013.01) [A61K 9/48 (2013.01); A61K 31/137 (2013.01); A61P 3/04 (2018.01); A61P 3/06 (2018.01); A61P 3/10 (2018.01); A61P 9/00 (2018.01); A61P 9/04 (2018.01); A61P 9/06 (2018.01); A61P 9/10 (2018.01); A61P 9/12 (2018.01); A61P 43/00 (2018.01); A61K 2300/00 (2013.01)]
AS A RESULT OF REEXAMINATION, IT HAS BEEN DETERMINED THAT:
Claims 1-20 are cancelled.
At the time of issuance and publication of this certificate, the patent remains subject to pending reissue application number 18/135,475 filed Apr. 17, 2023. The claim content of the patent may be subsequently revised if a reissue patent is issued from the reissue application.
1. A method of treating overweight or obesity in a subject having an increased risk of adverse cardiovascular out-comes, the method comprising:
treating the subject for overweight or obesity by administering to the subject a daily dose of 32 mg of naltrexone, or a pharmaceutically acceptable salt thereof, and 360 mg bupropion, or a pharmaceutically acceptable salt thereof, for a period of at least 12 weeks.